​

Alkermes (ALKS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ALKS Stock Forecast

Alkermes (ALKS) stock forecast, based on 26 Wall Street analysts, predicts a 12-month average price target of $44.57, with a high of $47.00 and a low of $42.00. This represents a 49.56% increase from the last price of $29.80.

$20 $26 $32 $38 $44 $50 High: $47 Avg: $44.57 Low: $42 Last Closed Price: $29.8

ALKS Stock Rating

Alkermes stock's rating consensus is Buy, based on 26 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 13 Buy (50.00%), 11 Hold (42.31%), 2 Sell (7.69%), and 0 Strong Sell (0.00%).

Buy
Total 26 0 2 11 13 Strong Sell Sell Hold Buy Strong Buy

ALKS Price Target Upside V Benchmarks

TypeNameUpside
StockAlkermes49.56%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts3711
Avg Price Target$45.67$44.86$42.64
Last Closing Price$29.80$29.80$29.80
Upside/Downside53.26%50.54%43.09%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 252115--18
Sep, 252105--17
Aug, 252105--17
Jul, 25295--16
Jun, 25286--16
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 27, 2025Mizuho Securities$45.00$29.7651.21%51.01%
Oct 23, 2025David AmsellemPiper Sandler$45.00$31.0944.74%51.01%
Oct 22, 2025RBC Capital$47.00$31.0951.17%57.72%
Sep 26, 2025Alkermes to OutperformRBC Capital$44.00$28.1456.36%47.65%
Sep 09, 2025Needham$43.00$27.8554.40%44.30%
Sep 09, 2025Douglas TsaoH.C. Wainwright$46.00$27.7765.65%54.36%
Sep 02, 2025Wells Fargo$44.00$29.4049.66%47.65%
Jun 17, 2025Ashwani VermaUBS$42.00$29.7741.08%40.94%
Dec 05, 2024David AmsellemPiper Sandler$37.00$31.2518.40%24.16%
Nov 13, 2024Vamil DivanMizuho Securities$40.00$26.0753.43%34.23%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 23, 2025Piper SandlerOverweightOverweighthold
Oct 22, 2025RBC CapitalOutperformOutperformhold
Oct 22, 2025H.C. WainwrightNeutralNeutralhold
Sep 26, 2025RBC CapitalUnderperformOutperformupgrade
Sep 09, 2025H.C. WainwrightNeutralNeutralhold
Sep 02, 2025Wells FargoOverweightinitialise
Jul 15, 2025Goldman SachsBuyinitialise
Jun 17, 2025UBSSector PerformBuyupgrade
May 28, 2025NeedhamNeutralBuyinitialise
May 02, 2025H.C. WainwrightNeutralNeutralhold

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.70$-0.30$-0.97$2.14$2.22----
Avg Forecast$0.36$0.58$0.23$1.60$2.62$1.74$1.97$1.68$1.80
High Forecast$0.37$0.61$0.24$1.79$2.80$1.98$2.76$2.60$1.88
Low Forecast$0.35$0.57$0.22$1.51$2.39$1.23$0.34$0.49$1.68
Surprise %-294.44%-151.72%-521.74%33.75%-15.27%----

Revenue Forecast

$1B $1B $1B $1B $2B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.04B$1.17B$1.11B$1.66B$1.56B----
Avg Forecast$1.03B$1.16B$1.10B$1.65B$1.51B$1.41B$1.46B$1.43B$1.47B
High Forecast$1.06B$1.20B$1.13B$1.67B$1.52B$1.46B$1.47B$1.43B$1.52B
Low Forecast$1.00B$1.13B$1.05B$1.62B$1.48B$1.35B$1.45B$1.42B$1.39B
Surprise %1.15%1.35%1.37%0.85%3.27%----

Net Income Forecast

$-1B $-600M $-200M $200M $600M $1B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-110.86M$-48.17M$-158.27M$355.76M$367.07M----
Avg Forecast$60.53M$-151.10M$-447.50M$519.16M$441.17M$272.37M$211.64M$210.29M$304.67M
High Forecast$63.35M$-111.66M$-355.81M$625.33M$476.00M$336.78M$469.15M$441.92M$319.43M
Low Forecast$58.60M$-190.54M$-539.19M$412.99M$406.34M$207.96M$57.12M$83.33M$285.39M
Surprise %-283.15%-68.12%-64.63%-31.47%-16.80%----

ALKS Forecast FAQ

Is Alkermes stock a buy?

Alkermes stock has a consensus rating of Buy, based on 26 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 13 Buy, 11 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Alkermes is a favorable investment for most analysts.

What is Alkermes's price target?

Alkermes's price target, set by 26 Wall Street analysts, averages $44.57 over the next 12 months. The price target range spans from $42 at the low end to $47 at the high end, suggesting a potential 49.56% change from the previous closing price of $29.8.

How does Alkermes stock forecast compare to its benchmarks?

Alkermes's stock forecast shows a 49.56% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Alkermes over the past three months?

  • October 2025: 11.11% Strong Buy, 61.11% Buy, 27.78% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 11.76% Strong Buy, 58.82% Buy, 29.41% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 11.76% Strong Buy, 58.82% Buy, 29.41% Hold, 0% Sell, 0% Strong Sell.

What is Alkermes’s EPS forecast?

Alkermes's average annual EPS forecast for its fiscal year ending in December 2025 is $1.74, marking a -21.62% decrease from the reported $2.22 in 2024. Estimates for the following years are $1.97 in 2026, $1.68 in 2027, and $1.8 in 2028.

What is Alkermes’s revenue forecast?

Alkermes's average annual revenue forecast for its fiscal year ending in December 2025 is $1.41B, reflecting a -9.71% decrease from the reported $1.56B in 2024. The forecast for 2026 is $1.46B, followed by $1.43B for 2027, and $1.47B for 2028.

What is Alkermes’s net income forecast?

Alkermes's net income forecast for the fiscal year ending in December 2025 stands at $272.37M, representing a -25.80% decrease from the reported $367.07M in 2024. Projections indicate $211.64M in 2026, $210.29M in 2027, and $304.67M in 2028.